Search
News
Gibraltar Q2 2026 earnings: OmniMax drives sales growth, but EPS declines
Gibraltar Industries’ Q2 2026 continuing-operations revenue rose 64.6% to $509.5 million, driven largely by OmniMax, while organic growth was 5%. GAAP diluted EPS fell 7.1% to $0.92 and adjusted EPS slipped 1.8% to $1.11 as higher interest expense and integration-related costs offset the increase in scale. Adjusted EBITDA climbed 59.7% to $88.0 million. Residential produced 83% of quarterly revenue, Agtech margins improved, and Infrastructure weakened. Gibraltar reiterated its full-year 2026 outlook while continuing OmniMax integration and synergy work.
TradingKey
Wed, Aug 5
Griffon Fiscal Q3 2026 Earnings: Revenue Rises 7% as Margins Narrow
Griffon Corporation’s fiscal Q3 2026 revenue rose 7% to $481.4 million, driven mainly by 6% favorable price and mix, while adjusted EPS from continuing operations increased to $1.51 from $1.39. Adjusted EBITDA advanced 2% to $124.8 million, but gross and adjusted EBITDA margins narrowed as material and SG&A costs increased. The company ended June with 2.2x net leverage, projected fiscal 2026 revenue of $1.8 billion and adjusted EBITDA of $458 million, and substantially completed its shift to a pure-play building products company.
TradingKey
Wed, Aug 5
DISCO Q2 2026 Earnings: Revenue Grows as GAAP Loss Narrows
DISCO’s Q2 2026 revenue rose 13% to $43.1 million, while GAAP net loss narrowed to $8.7 million from $10.8 million and loss per share improved to $0.13 from $0.18. However, adjusted EBITDA deteriorated to a $3.4 million loss from $2.7 million as underlying operating costs remained elevated. Software revenue reached $36.8 million, and customers generating more than $100,000 over the trailing 12 months increased 10% to 354. Q3 guidance calls for $43.75 million to $45.75 million in total revenue and a smaller adjusted EBITDA loss.
TradingKey
Wed, Aug 5
Seres Q2 2026 Earnings: A $25 Million VOWST Gain Drives Quarterly Profit
Seres Therapeutics reported Q2 2026 grant revenue of $736,000 and diluted EPS of $0.47, compared with no revenue and a $2.27 loss per share a year earlier. Net income reached $4.6 million, but the result was driven by a $25 million gain tied to the VOWST milestone buyout while operations still lost $21.3 million. The company ended June with $15.6 million in cash and expects funding to last through Q1 2027. SER-155 also posted an 80% day-15 response rate in a 15-patient irEC study.
TradingKey
Wed, Aug 5
Orion Fiscal Q1 2027 Earnings: Margin Expansion Restores Profitability
Orion Energy Systems’ fiscal Q1 2027 revenue rose 32% to $25.7 million, while diluted EPS improved to $0.47 from a $0.37 loss a year earlier. Gross margin expanded 450 basis points to 34.6%, helping the company deliver $2.0 million of net income and a seventh consecutive quarter of positive adjusted EBITDA. LED lighting and EV charging led growth, operating cash flow turned positive, and Orion reiterated fiscal 2027 revenue guidance of $95 million to $97 million with positive adjusted EBITDA. The main watchpoints are large-project timing, EV funding uncertainty, tariffs, and ERP execution.
TradingKey
Wed, Aug 5
Brink’s Q2 2026 earnings: Adjusted EBITDA grows despite GAAP margin pressure
Brink’s reported Q2 2026 revenue of $1.392 billion, up 7% year over year, while GAAP diluted EPS rose 4% to $1.07. Adjusted EBITDA increased 11% to $257.2 million, supported by higher segment profit and continued mid-teens-or-better organic growth in ATM managed services and digital retail solutions. However, GAAP operating margin fell 70 basis points to 9.6% as corporate, NCR Atleos acquisition, and transformation costs offset operating gains. The company also issued Q3 ranges and maintained its 2026 operating framework.
TradingKey
Wed, Aug 5
BioCryst Q2 2026 earnings: Licensing revenue lifts operating profit
BioCryst’s Q2 2026 revenue rose 34% to $218.3 million, while diluted EPS increased to $0.30 from $0.02 and GAAP operating profit reached $98.5 million. The quarter benefited from $55.7 million of navenibart European licensing revenue; ORLADEYO revenue was $158.2 million, up 1% reported and 10% on a comparable basis excluding Europe. BioCryst maintained 2026 ORLADEYO guidance at $625 million to $645 million, raised total revenue guidance to $690 million to $715 million, and retained its lower non-GAAP operating expense outlook.
TradingKey
Wed, Aug 5
EyePoint Q2 2026 earnings: Phase 3 spending widens the net loss
EyePoint’s Q2 2026 revenue fell to $0.5 million from $5.3 million, while net loss widened to $94.5 million and diluted loss per share increased to $1.09 from $0.85. Operating expenses rose about 45% to $97.9 million, mainly because of DURAVYU Phase 3 trials in wet AMD and DME and manufacturing scale-up. EyePoint ended June with $180 million in cash and investments, which it expects to fund operations into Q4 2027. The next major milestones are LUGANO data in August 2026 and LUCIA results in Q4 2026.
TradingKey
Wed, Aug 5
Geron Q2 2026 earnings: RYTELO revenue grows as inventory costs weigh on margins
Geron’s Q2 2026 earnings showed total revenue of $57.48 million, up 17.2% year over year, while RYTELO net product revenue rose 11% sequentially to $57.47 million. The company recorded a $16.68 million net loss, or $0.02 per diluted share, as non-cash inventory-related expenses lifted cost of goods sold to $9.24 million. Geron ended June with $326.9 million in cash, cash equivalents, restricted cash and marketable securities, and reiterated full-year RYTELO revenue guidance of $220 million to $240 million.
TradingKey
Wed, Aug 5
Kymera Q2 2026 Earnings: Milestone Revenue Narrows Net Loss
Kymera Therapeutics’ Q2 2026 collaboration revenue rose to $65.0 million from $11.5 million, driven by $45 million from Gilead and $20 million from Sanofi. Net loss narrowed to $61.2 million, or $0.62 per share, even as R&D spending increased to $119.5 million. The company ended June with $1.5 billion in cash and investments, supporting a stated runway into 2029. Operationally, Kymera completed enrollment in the KT-621 Phase 2b atopic dermatitis trial nearly six months early and moved the expected topline readout forward to year-end 2026.
TradingKey
Wed, Aug 5
J&J Snack Foods Fiscal Q3 2026 Earnings: Margin Gains Could Not Offset Lower Sales
J&J Snack Foods’ fiscal 2026 third-quarter net sales fell 6.2% to $426.0 million, while diluted EPS declined 16.8% to $1.88. Gross margin expanded 240 basis points to 35.5% as Apollo initiatives and a better mix supported gross profit, but higher distribution costs and a difficult comparison with a prior-year insurance gain pressured operating income. Adjusted EPS was $1.96, down 2.0%. Food Service and Frozen Beverages sales declined, while Retail Supermarket sales increased modestly but produced lower operating profit. Nine-month operating cash flow edged higher to $100.4 million.
TradingKey
Wed, Aug 5
Royalty Pharma Q2 2026 earnings: Royalty receipts rise 14% as guidance increases
Royalty Pharma’s Q2 2026 earnings showed Portfolio Receipts of $773 million, up 6%, as Royalty Receipts increased 14% to $768 million on growth from Tremfya, Voranigo, Imdelltra and Evrysdi. Cash generation improved as lower operating and development-stage funding payments supported liquidity, while attributable net income declined because of a provision for changes in expected royalty-asset cash flows. Royalty Pharma raised full-year Portfolio Receipts guidance to $3.4 billion-$3.5 billion, with expected Royalty Receipts growth of 7%-10%.
TradingKey
Wed, Aug 5
Kaltura Q2 2026 Earnings: Subscription Growth Expands Gross Margin
Kaltura’s Q2 2026 revenue rose 5% to $46.9 million, while GAAP diluted loss per share improved to $0.04 from $0.05. Subscription revenue increased 8% to $45.6 million and GAAP gross margin expanded to 74% from 70%, helping adjusted EBITDA reach $5.9 million. Growth was concentrated in Enterprise, Education and Technology, while Media & Telecom revenue fell 10%. Operating cash flow turned to a $2.0 million outflow, and Q3 adjusted EBITDA guidance of $2.0 million to $3.0 million is below the second-quarter result.
TradingKey
Wed, Aug 5
Astec Q2 2026 Earnings: Sales Rise as EBITDA Guidance Is Cut
Astec Industries’ Q2 2026 net sales rose 23.6% to $408.1 million, led by 43.0% growth in Materials Solutions, while diluted EPS fell to $0.45 from $0.72. Adjusted EBITDA increased 26.0% to $42.6 million and backlog climbed 57.9% to $601.1 million, but GAAP operating margin contracted 150 basis points to 5.0%. Management lowered full-year adjusted EBITDA guidance to $160 million-$175 million from $170 million-$190 million because macro conditions are delaying asphalt-plant shipments. Quarterly free cash flow declined to $4.7 million from $9.0 million.
TradingKey
Wed, Aug 5
TeraWulf Q2 2026 earnings: HPC reaches 71% of revenue as losses widen
TeraWulf’s Q2 2026 revenue fell approximately 6% to $44.8 million, while diluted loss per share widened to $1.94 from $0.05. HPC lease revenue reached $31.9 million, or 71% of sales, partly offsetting a 73% decline in digital asset revenue. The company recorded a $939.9 million attributable net loss, heavily affected by a $755.7 million warrant fair-value charge, and adjusted EBITDA turned negative at $18.3 million. Lake Mariner capacity reached 102 MW after quarter-end, with another 336 MW under construction and cash plus restricted cash of about $3.0 billion.
TradingKey
Wed, Aug 5
Advantage Solutions Q2 2026 earnings: Revenue grew while margins narrowed
Advantage Solutions (NASDAQ: ADV) reported Q2 2026 revenue of $889.5 million, up 1.8% year over year, but its net loss widened to $62.7 million and adjusted EBITDA fell 12.2% to $75.8 million. Experiential Services revenue rose 19.7% and helped offset a 20.1% decline in Branded Services, while Retailer Services faced project timing and execution costs. The company ended the quarter with $102.3 million in cash, maintained its full-year revenue and adjusted EBITDA outlook, and lowered its net interest expense and capital spending ranges.
TradingKey
Wed, Aug 5
Shopify Q2 2026 earnings: Revenue rose 34% as operating leverage improved
Shopify’s Q2 2026 revenue increased 34% year over year to $3.58 billion, while GMV rose 32% to $115.57 billion. Operating income climbed 68% to $488 million, and free cash flow reached $654 million with an 18% margin. GAAP net income of $1.50 billion was heavily influenced by equity investment gains; excluding that impact, net income was $439 million. Shopify expects low-thirties revenue growth for Q3, with gross profit growth in the mid-to-high twenties and a high-teens to low-twenties free cash flow margin.TradingKey
Wed, Aug 5
GlobalFoundries Q2 2026 earnings: Revenue rose 6% as gross margin expanded
GlobalFoundries’ Q2 2026 revenue rose 6% year over year to $1.786 billion, while IFRS diluted EPS fell to $0.30 from $0.41. IFRS gross margin expanded 410 basis points to 28.3%, but higher R&D and SG&A spending reduced operating profit and net income. Operating cash flow was $405 million, while adjusted free cash flow slipped to negative $3 million as investment spending increased. The company guided Q3 revenue to $1.885 billion, plus or minus $25 million, with a 29.5% IFRS gross-margin midpoint.
TradingKey
Wed, Aug 5
Gilat Q2 2026 earnings: Revenue growth lifts adjusted EBITDA while GAAP profit falls
Gilat Satellite Networks’ Q2 2026 revenue rose 17% to $122.7 million, and adjusted EBITDA increased 31% to $15.4 million. However, GAAP operating income fell to $4.7 million and diluted EPS declined to $0.10 as operating expenses increased and the diluted share count expanded. All three segments grew, led by Commercial revenue, while quarterly operating cash flow turned negative amid inventory growth and lower customer advances. Gilat reiterated 2026 revenue guidance of $500 million to $520 million and adjusted EBITDA guidance of $61 million to $66 million, with the Comtech transaction still expected to close near year-end.TradingKey
Wed, Aug 5
Orthofix Q2 2026 earnings: Revenue grew as adjusted EBITDA margin narrowed
Orthofix Medical reported Q2 2026 net sales of $210.9 million, up 3.8% year over year, while its GAAP net loss widened to $15.8 million, or $0.39 per diluted share. Adjusted EBITDA was $20.1 million, and its margin on pro forma sales fell to 9.6% from 10.3%. Global Limb Reconstruction led growth, Medicare reimbursement for bone growth stimulators was restored, and the company raised full-year net sales guidance to $845 million-$855 million and adjusted EBITDA guidance to $95 million-$98 million.
TradingKey
Wed, Aug 5
Featured Tools
Top News
Amazon Shares Plunge 11% After Hours as Q3 Revenue Misses Estimates, Free Cash Flow Negative $33.456 Billion
Amazon Stock Forecast: AMZN Needs a Close Above $258 as Q3 Tests Its AI Spending
Marvell’s Proposed Acquisition of Lumentum Sparks Pre-Market Divergence in Optical Communications Stocks: MRVL Falls Over 11%, LITE Rises Over 4%, COHR Slips 0.63%
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
Amazon Q3 Earnings Preview: AWS Growth Expected to Rise to 41%, Wall Street Top Price Target $400